Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0O9EB
|
||||
Former ID |
DNC013500
|
||||
Drug Name |
3-(butylsulfinyl)-1,1,1-trifluoropropan-2-one
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C7H11F3O2S
|
||||
Canonical SMILES |
CCCCS(=O)CC(=O)C(F)(F)F
|
||||
InChI |
1S/C7H11F3O2S/c1-2-3-4-13(12)5-6(11)7(8,9)10/h2-5H2,1H3
|
||||
InChIKey |
MFTBLUCHUFLEGX-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Liver carboxylesterase | Target Info | Inhibitor | [1] | |
KEGG Pathway | Drug metabolism - other enzymes | ||||
Metabolic pathways | |||||
Pathway Interaction Database | E2F transcription factor network | ||||
WikiPathways | NRF2 pathway | ||||
Nuclear Receptors Meta-Pathway | |||||
Heroin metabolism | |||||
Irinotecan Pathway | |||||
Fluoropyrimidine Activity | |||||
Phase I biotransformations, non P450 | |||||
References | |||||
REF 1 | Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. Epub 2007 Nov 26.Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hydrolase (FAAH). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.